Therapeutic drug monitoring of antifungal therapies: do we really need it and what are the best practices?

References

• WHO. WHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis An Off Publ Infect Dis Soc Am. 2016;62(4):e1–50. doi: 10.1093/cid/civ933
   PubMed Web of Science ®Google Scholar
• Husain S, Camargo JF. Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 [cited 2022 Jun 21];33(9). doi: 10.1111/ctr.13544
   Web of Science ®Google Scholar
• Hoenigl M, Salmanton-García J, Walsh TJ, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infect Dis. 2021;21:e246–e257. [cited 2022 Jun 20]. Available from: https://pubmed.ncbi.nlm.nih.gov/33606997/
   PubMed Web of Science ®Google Scholar
• Boyer J, Kriegl L, Krause R, et al. Dark mold infections in solid organ transplant recipients. Curr Fungal Infect Rep. 2022;16:107–115. doi: 10.1007/s12281-022-00436-y
   Web of Science ®Google Scholar
• Bartoletti M, Pascale R, Cricca M, et al. Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: a prospective study. Clin Infect Dis An Off Publ Infect Dis Soc Am. 2021;73(11):e3606–e3614. doi: 10.1093/cid/ciaa1065
   PubMed Web of Science ®Google Scholar
• Lewis RE, Andes DR. Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions. Curr Opin Infect Dis. 2021;34(4):288–296. doi: 10.1097/QCO.0000000000000740
   PubMed Web of Science ®Google Scholar
• McCreary EK, Davis MR, Narayanan N, et al. Utility of triazole antifungal therapeutic drug monitoring: insights from the society of infectious diseases pharmacists: endorsed by the mycoses study group Education and Research Consortium. Pharmacotherapy. 2023;43(10):1043–1050. doi: 10.1002/phar.2850
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Alffenaar J-W, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper(). Intensive care Med. 2020;46(6):1127–1153. doi: 10.1007/s00134-020-06050-1
   PubMed Web of Science ®Google Scholar
• Kim HY, Baldelli S, Märtson A-G, et al. Therapeutic drug monitoring of the echinocandin antifungal agents: is there a role in clinical practice? A position statement of the Anti-Infective drugs Committee of the International Association of therapeutic drug monitoring and clinical toxicology. Ther Drug Monit. 2022;44(1):198–214. doi: 10.1097/FTD.0000000000000931
   PubMed Web of Science ®Google Scholar
• Chau MM, Daveson K, Alffenaar J-W, et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021. Intern Med J. 2021;51(Suppl 7):37–66. doi: 10.1111/imj.15587
   PubMedGoogle Scholar
• Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69(5):1162–1176. doi: 10.1093/jac/dkt508
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet (London, England). 2003;362:1142–1151. doi: 10.1016/S0140-6736(03)14472-8
   PubMed Web of Science ®Google Scholar
• Douglas CM. Fungal beta(1,3)-D-glucan synthesis. Med Mycol. 2001;39(Suppl 1):55–66. doi: 10.1080/mmy.39.1.55.66
   PubMed Web of Science ®Google Scholar
• Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009;43(10):1647–1657. doi: 10.1345/aph.1M237
   PubMed Web of Science ®Google Scholar
• Deshkar S, Patil N, Amberkar S, et al. Identification and antifungal drug susceptibility pattern of Candida auris in India. J Glob Infect Dis. 2022;14(4):131–135. doi: 10.4103/jgid.jgid_44_22
   PubMed Web of Science ®Google Scholar
• Maphanga TG, Naicker SD, Kwenda S, et al. In vitro antifungal resistance of Candida auris isolates from bloodstream infections, South Africa. Antimicrob Agents Chemother. 2021;65(9):e0051721. doi: 10.1128/AAC.00517-21
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2012;18(Suppl 7):19–37. doi: 10.1111/1469-0691.12039
   PubMed Web of Science ®Google Scholar
• Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433–444. doi: 10.3324/haematol.2016.152900
   PubMed Web of Science ®Google Scholar
• Aslam S, Rotstein C. Candida infections in solid organ transplantation: guidelines from the American Society of transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):1–11. doi: 10.1111/ctr.13623
   Google Scholar
• Gómez-López A. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2020;26(11):1481–1487. doi: 10.1016/j.cmi.2020.05.037
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2002;46(6):1857–1869. doi: 10.1128/AAC.46.6.1857-1869.2002
   PubMed Web of Science ®Google Scholar
• Gumbo T, Drusano GL, Liu W, et al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother. 2007;51(3):968–974. doi: 10.1128/AAC.01337-06
   PubMed Web of Science ®Google Scholar
• Andes DR, Diekema DJ, Pfaller MA, et al. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008;52(10):3497–3503. doi: 10.1128/AAC.00478-08
   PubMed Web of Science ®Google Scholar
• Nguyen KT, Ta P, Hoang BT, et al. Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. Antimicrob Agents Chemother. 2009;53:3347–3352. doi: 10.1128/AAC.01480-08
   PubMed Web of Science ®Google Scholar
• Lepak AJ, Zhao M, VanScoy B, et al. Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an Extended-Interval dosing design. Antimicrob Agents Chemother. 2018;62(2):62. doi: 10.1128/AAC.02154-17
   Web of Science ®Google Scholar
• Lepak AJ, Zhao M, Andes DR. Pharmacodynamic evaluation of rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model. Antimicrob Agents Chemother. 2018;62(11):62. doi: 10.1128/AAC.01572-18
   Web of Science ®Google Scholar
• van Vianen W, de Marie S, ten Kate MT, et al. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother. 2006;57(4):732–740. doi: 10.1093/jac/dkl015
   PubMed Web of Science ®Google Scholar
• Andes D, Diekema DJ, Pfaller MA, et al. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against candida species. Antimicrob Agents Chemother. 2010;54(6):2497–2506. doi: 10.1128/AAC.01584-09
   PubMed Web of Science ®Google Scholar
• van der Elst KCM, Veringa A, Zijlstra JG, et al. Low caspofungin exposure in patients in intensive care units. Antimicrob Agents Chemother. 2017;61(2):61. doi: 10.1128/AAC.01582-16
   Web of Science ®Google Scholar
• Adembri C, Villa G, Rosi E, et al. Caspofungin PK in critically ill patients after the first and fourth doses: suggestions for therapeutic drug monitoring? J Chemother. 2020;32(3):124–131. doi: 10.1080/1120009X.2020.1737783
   PubMed Web of Science ®Google Scholar
• Lempers VJ, Schouten JA, Hunfeld NG, et al. Altered micafungin Pharmacokinetics in intensive care unit patients. Antimicrob Agents Chemother. 2015;59(8):4403–4409. doi: 10.1128/AAC.00623-15
   PubMed Web of Science ®Google Scholar
• Brüggemann RJM, Middel-Baars V, de Lange DW, et al. Pharmacokinetics of Anidulafungin in critically ill intensive care unit patients with suspected or proven invasive fungal infections. Antimicrob Agents Chemother. 2017;61(2):61. doi: 10.1128/AAC.01894-16
   Web of Science ®Google Scholar
• Sinnollareddy MG, Roberts JA, Lipman J, et al. Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. Crit Care. 2015;19(1):33. doi: 10.1186/s13054-015-0758-3
   PubMed Web of Science ®Google Scholar
• Boonstra JM, van der Elst KC, Veringa A, et al. Pharmacokinetic properties of micafungin in critically ill patients diagnosed with invasive candidiasis. Antimicrob Agents Chemother. 2017;61(12):61. doi: 10.1128/AAC.01398-17
   Web of Science ®Google Scholar
• Wasmann RE, Smit C, Ter Heine R, et al. Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults. J Antimicrob Chemother. 2019;74(4):978–985. doi: 10.1093/jac/dky554
   PubMed Web of Science ®Google Scholar
• Wasmann RE, Ter Heine R, van Dongen EP, et al. Pharmacokinetics of Anidulafungin in obese and normal-weight adults. Antimicrob Agents Chemother. 2018;62(7):62. doi: 10.1128/AAC.00063-18
   Web of Science ®Google Scholar
• Hoenigl M, Sprute R, Arastehfar A, et al. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opin Investig Drugs. 2022;31(8):795–812. doi: 10.1080/13543784.2022.2086120
   PubMed Web of Science ®Google Scholar
• Märtson A-G, van der Elst KCM, Veringa A, et al. Caspofungin Weight-Based dosing supported by a population Pharmacokinetic model in critically ill patients. Antimicrob Agents Chemother. 2020;64(9):64. doi: 10.1128/AAC.00905-20
   Web of Science ®Google Scholar
• Strenger V, Farowski F, Müller C, et al. Low penetration of caspofungin into cerebrospinal fluid following intravenous administration of standard doses. Int J Antimicrob Agents. 2017;50(2):272–275. doi: 10.1016/j.ijantimicag.2017.02.024
   PubMed Web of Science ®Google Scholar
• Gioia F, Gomez-Lopez A, Alvarez ME, et al. Pharmacokinetics of echinocandins in suspected candida peritonitis: a potential risk for resistance. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2020;101:24–28. doi: 10.1016/j.ijid.2020.09.019
   PubMed Web of Science ®Google Scholar
• Pound MW, Townsend ML, Drew RH. Echinocandin pharmacodynamics: review and clinical implications. J Antimicrob Chemother. 2010;65(6):1108–1118. doi: 10.1093/jac/dkq081
   PubMed Web of Science ®Google Scholar
• Cornely OA, Vehreschild JJ, Vehreschild MJGT, et al. Phase II dose escalation study of caspofungin for invasive aspergillosis. Antimicrob Agents Chemother. 2011;55(12):5798–5803. doi: 10.1128/AAC.05134-11
   PubMed Web of Science ®Google Scholar
• Sirohi B, Powles RL, Chopra R, et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;38(1):47–51. doi: 10.1038/sj.bmt.1705398
   PubMed Web of Science ®Google Scholar
• Wagener J, Loiko V. Recent insights into the paradoxical effect of echinocandins. J Fungi. 2017;4(1):5. (Basel, Switzerland). doi: 10.3390/jof4010005
   Web of Science ®Google Scholar
• Boyer J, Feys S, Zsifkovits I, et al. Treatment of invasive aspergillosis: how It’s going, where It’s heading. Mycopathologia. 2023;188(5):667–681. doi: 10.1007/s11046-023-00727-z
   PubMed Web of Science ®Google Scholar
• Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73(9):919–934. doi: 10.1007/s40265-013-0069-4
   PubMed Web of Science ®Google Scholar
• Aigner M, Lass-Flörl C. Encochleated amphotericin B: is the oral availability of amphotericin B finally reached? J Fungi. 2020;6(2):66. (Basel, Switzerland). doi: 10.3390/jof6020066
   Web of Science ®Google Scholar
• Egger M, Bellmann R, Krause R, et al. Salvage Treatment for Invasive Aspergillosis and Mucormycosis: challenges, recommendations and future considerations. Infect Drug Resist. 2023;16:2167–2178. doi: 10.2147/IDR.S372546
   PubMed Web of Science ®Google Scholar
• Groll AH, Rijnders BJA, Walsh TJ, et al. Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B. Clin Infect Dis An Off Publ Infect Dis Soc Am. 2019;68(Supplement_4):S260–S274. doi: 10.1093/cid/ciz076
   PubMed Web of Science ®Google Scholar
• Wirth F, Ishida K. Antifungal drugs: an updated review of central nervous system pharmacokinetics. Mycoses. 2020;63(10):1047–1059. doi: 10.1111/myc.13157
   PubMed Web of Science ®Google Scholar
• Strenger V, Meinitzer A, Donnerer J, et al. Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B. J Antimicrob Chemother. 2014;69(9):2522–2526. doi: 10.1093/jac/dku148
   PubMed Web of Science ®Google Scholar
• van der Voort PHJ, Boerma EC, Yska JP. Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis. J Antimicrob Chemother. 2007;59(5):952–956. doi: 10.1093/jac/dkm074
   PubMed Web of Science ®Google Scholar
• Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014;27(1):68–88.
   PubMed Web of Science ®Google Scholar
• Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother. 2001;45(3):922–926. doi: 10.1128/AAC.45.3.922-926.2001
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Tam VH, Chi J, et al. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2006;50(2):469–473. doi: 10.1128/AAC.50.2.469-473.2006
   PubMed Web of Science ®Google Scholar
• Gondal JA, Swartz RP, Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother. 1989;33(9):1544–1548. doi: 10.1128/AAC.33.9.1544
   PubMed Web of Science ®Google Scholar
• Adler-Moore JP, Chiang SM, Satorius A, et al. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J Antimicrob Chemother. 1991;28(Suppl B):63–71. doi: 10.1093/jac/28.suppl_B.63
   PubMed Web of Science ®Google Scholar
• Karyotakis NC, Anaissie EJ. Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice. Antimicrob Agents Chemother. 1994;38(11):2660–2662. doi: 10.1128/AAC.38.11.2660
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiload trial). Clin Infect Dis An Off Publ Infect Dis Soc Am. 2007;44(10):1289–1297. doi: 10.1086/514341
   PubMed Web of Science ®Google Scholar
• Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis An Off Publ Infect Dis Soc Am. 1998;27(6):1406–1412. doi: 10.1086/515033
   PubMed Web of Science ®Google Scholar
• Duschinsky R, Pleven E, Heidelberger C. The synthesis of 5-fluoropyrimidines. J Am Chem Soc. 1957;79:4559–4560. doi: 10.1021/ja01573a087
   Web of Science ®Google Scholar
• Benson JM, Nahata MC. Clinical use of systemic antifungal agents. Clin Pharm. 1988;7(6):424–438.
   PubMedGoogle Scholar
• Polak A, Scholer HJ. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy. 1975;21(3–4):113–130. doi: 10.1159/000221854
   PubMed Web of Science ®Google Scholar
• Waldorf AR, Polak A. Mechanisms of action of 5-fluorocytosine. Antimicrob Agents Chemother. 1983;23(1):79–85. doi: 10.1128/AAC.23.1.79
   PubMed Web of Science ®Google Scholar
• Sigera LSM, Denning DW. Flucytosine and its clinical usage. Ther Adv Infect Dis. 2023;10:20499361231161388. doi: 10.1177/20499361231161387
   Web of Science ®Google Scholar
• Nett JE, Andes DR. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. Infect Dis Clin North Am. 2016;30(1):51–83. doi: 10.1016/j.idc.2015.10.012
   PubMed Web of Science ®Google Scholar
• Andes D, van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother. 2000;44(4):938–942. doi: 10.1128/AAC.44.4.938-942.2000
   PubMed Web of Science ®Google Scholar
• Hope WW, Warn PA, Sharp A, et al. Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect. Antimicrob Agents Chemother. 2006;50(11):3680–3688. doi: 10.1128/AAC.00369-06
   PubMed Web of Science ®Google Scholar
• Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53(1):24–34. doi: 10.1128/AAC.00705-08
   PubMed Web of Science ®Google Scholar
• Stamm AM, Diasio RB, Dismukes WE, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987;83(2):236–242. doi: 10.1016/0002-9343(87)90691-7
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Frame PT. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother. 1977;11(2):244–247. doi: 10.1128/AAC.11.2.244
   PubMed Web of Science ®Google Scholar
• Vermes A, van Der Sijs H, Guchelaar HJ. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy. 2000;46(2):86–94. doi: 10.1159/000007260
   PubMed Web of Science ®Google Scholar
• Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979;301(3):126–131. doi: 10.1056/NEJM197907193010303
   PubMed Web of Science ®Google Scholar
• Normark S, Schönebeck J. In vitro studies of 5-fluorocytosine resistance in Candida albicans and torulopsis glabrata. Antimicrob Agents Chemother. 1972;2(3):114–121. doi: 10.1128/AAC.2.3.114
   PubMed Web of Science ®Google Scholar
• Stott KE, Hope WW. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. J Antimicrob Chemother. 2017;72(suppl_1):i12–i18. doi: 10.1093/jac/dkx029
   PubMedGoogle Scholar
• Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther. 1978;24(3):333–342. doi: 10.1002/cpt1978243333
   PubMed Web of Science ®Google Scholar
• Jenks JD, Mehta SR, Hoenigl M. Broad spectrum triazoles for invasive mould infections in adults: which drug and when? Med Mycol. 2019;57(Supplement_2):S168–S178. doi: 10.1093/mmy/myy052
   PubMedGoogle Scholar
• Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther. 2009;7(8):981–998. doi: 10.1586/eri.09.67
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649–663. doi: 10.2165/00003088-200645070-00002
   PubMed Web of Science ®Google Scholar
• Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47(10):3165–3169. doi: 10.1128/AAC.47.10.3165-3169.2003
   PubMed Web of Science ®Google Scholar
• Han K, Capitano B, Bies R, et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother. 2010;54(10):4424–4431. doi: 10.1128/AAC.00504-10
   PubMed Web of Science ®Google Scholar
• Seyedmousavi S, Mouton JW, Melchers WJG, et al. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother. 2014;17(3):37–50. doi: 10.1016/j.drup.2014.06.001
   Google Scholar
• Patterson TF, GR T 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis An Off Publ Infect Dis Soc Am. 2016;63(4):e1–e60. doi: 10.1093/cid/ciw326
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46(8):2546–2553. doi: 10.1128/AAC.46.8.2546-2553.2002
   PubMed Web of Science ®Google Scholar
• Ohbuchi M, Yoshinari K, Kaneko H, et al. Coordinated roles of pregnane X receptor and constitutive androstane receptor in autoinduction of voriconazole metabolism in mice. Antimicrob Agents Chemother. 2013;57(3):1332–1338. doi: 10.1128/AAC.01900-12
   PubMed Web of Science ®Google Scholar
• Shen J, Wang B, Wang S, et al. Effects of Voriconazole on the pharmacokinetics of Vonoprazan in rats. Drug Des Devel Ther. 2020;14:2199–2206. doi: 10.2147/DDDT.S255427
   PubMed Web of Science ®Google Scholar
• Lee J-S, Kim H-S, Jung Y-S, et al. Pharmacokinetic drug interaction between tofacitinib and voriconazole in rats. Pharmaceutics. 2021;13(5):740. doi: 10.3390/pharmaceutics13050740
   PubMed Web of Science ®Google Scholar
• Dolton MJ, Ray JE, Chen S-A, et al. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56(9):4793–4799. doi: 10.1128/AAC.00626-12
   PubMed Web of Science ®Google Scholar
• Geist MJP, Egerer G, Burhenne J, et al. Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype. Antimicrob Agents Chemother U S. 2006;50(9):3227–3228. doi: 10.1128/AAC.00551-06
   PubMed Web of Science ®Google Scholar
• Murayama N, Imai N, Nakane T, et al. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007;73(12):2020–2026. doi: 10.1016/j.bcp.2007.03.012
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hou K, Liu F, et al. The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: systematic review and meta-analysis. Mycoses. 2021;64(8):860–873. doi: 10.1111/myc.13293
   PubMed Web of Science ®Google Scholar
• Cronin S, Chandrasekar PH. Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother. 2010;65(3):410–416. doi: 10.1093/jac/dkp464
   PubMed Web of Science ®Google Scholar
• Koselke E, Kraft S, Smith J, et al. Evaluation of the effect of obesity on voriconazole serum concentrations. J Antimicrob Chemother. 2012;67(12):2957–2962. doi: 10.1093/jac/dks312
   PubMed Web of Science ®Google Scholar
• Davies-Vorbrodt S, Ito JI, Tegtmeier BR, et al. Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review. Pharmacotherapy. 2013;33(1):22–30. doi: 10.1002/phar.1156
   PubMed Web of Science ®Google Scholar
• Gatti M, Fornaro G, Pasquini Z, et al. Impact of inflammation on voriconazole exposure in critically ill patients affected by probable COVID-19-Associated pulmonary aspergillosis. Antibiot. 2023;12(4):764. (Basel, Switzerland). doi: 10.3390/antibiotics12040764
   Google Scholar
• Bienvenu A-L, Pradat P, Plesa A, et al. Association between voriconazole exposure and Sequential Organ Failure Assessment (SOFA) score in critically ill patients. PLoS One. 2021;16(11):e0260656. doi: 10.1371/journal.pone.0260656
   PubMed Web of Science ®Google Scholar
• Van Daele R, Bekkers B, Lindfors M, et al. A large retrospective assessment of voriconazole exposure in patients treated with extracorporeal membrane oxygenation. Microorganisms. 2021;9(7):1543. doi: 10.3390/microorganisms9071543
   PubMed Web of Science ®Google Scholar
• Ronda M, Llop-Talaveron JM, Fuset M, et al. Voriconazole pharmacokinetics in critically Ill patients and extracorporeal membrane oxygenation support: a retrospective comparative case-control study. Antibiot. 2023;12(7):1100. (Basel, Switzerland). doi: 10.3390/antibiotics12071100
   Google Scholar
• Lyster H, Pitt T, Maunz O, et al. Variable sequestration of antifungals in an extracorporeal membrane oxygenation circuit. ASAIO J. 2023;69(3):309–314. doi: 10.1097/MAT.0000000000001802
   PubMed Web of Science ®Google Scholar
• Lempers VJ, Meuwese E, Mavinkurve-Groothuis AM, et al. Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients. Med Mycol. 2019;57(8):937–943. doi: 10.1093/mmy/myz006
   PubMed Web of Science ®Google Scholar
• Wang T, Zhu H, Sun J, et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents. 2014;44(5):436–442. doi: 10.1016/j.ijantimicag.2014.07.013
   PubMed Web of Science ®Google Scholar
• Boglione-Kerrien C, Morcet J, Scailteux L-M, et al. Contribution of voriconazole N-oxide plasma concentration measurements to voriconazole therapeutic drug monitoring in patients with invasive fungal infection. Mycoses. 2023;66(5):396–404. doi: 10.1111/myc.13570
   PubMed Web of Science ®Google Scholar
• Ueda K, Nannya Y, Kumano K, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol. 2009;89(5):592–599. doi: 10.1007/s12185-009-0296-3
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Duettmann W, Raggam RB, et al. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother. 2013;57(7):3262–3267. doi: 10.1128/AAC.00251-13
   PubMed Web of Science ®Google Scholar
• Park WB, Kim N-H, Kim K-H, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis An Off Publ Infect Dis Soc Am. 2012;55(8):1080–1087. doi: 10.1093/cid/cis599
   PubMed Web of Science ®Google Scholar
• Kang HM, Lee HJ, Cho EY, et al. The clinical significance of voriconazole therapeutic drug monitoring in children with invasive fungal infections. Pediatr Hematol Oncol. 2015;32(8):557–567. doi: 10.3109/08880018.2015.1088905
   PubMed Web of Science ®Google Scholar
• Cabral-Galeano E, Ruiz-Camps I, Len-Abad O, et al. Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital. Enferm Infec Microbiol Clin. 2015;33(5):298–302. doi: 10.1016/j.eimc.2014.09.005
   PubMed Web of Science ®Google Scholar
• Karthaus M, Lehrnbecher T, Lipp H-P, et al. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients—an evidence-based approach. Ann Hematol. 2015;94(4):547–556. doi: 10.1007/s00277-015-2333-z
   PubMed Web of Science ®Google Scholar
• Zhou PY, Lim TP, Tang SLS, et al. The utility of voriconazole therapeutic drug monitoring in a multi-racial cohort in Southeast Asia. J Glob Antimicrob Resist. 2020;21:427–433. doi: 10.1016/j.jgar.2019.12.004
   PubMed Web of Science ®Google Scholar
• Li H, Li M, Yan J, et al. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy. Basic Clin Pharmacol Toxicol. 2020;127(6):495–504. doi: 10.1111/bcpt.13465
   PubMed Web of Science ®Google Scholar
• Butler-Laporte G, Langevin M-C, Lemieux C, et al. Voriconazole therapeutic drug monitoring among lung transplant recipients receiving targeted therapy for invasive aspergillosis. Clin Transplant. 2022;36(8):e14709. doi: 10.1111/ctr.14709
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis An Off Publ Infect Dis Soc Am. 2008;46(2):201–211. doi: 10.1086/524669
   PubMed Web of Science ®Google Scholar
• Luong M-L, Al-Dabbagh M, Groll AH, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother. 2016;71(7):1786–1799. doi: 10.1093/jac/dkw099
   PubMed Web of Science ®Google Scholar
• Lee J, Ng P, Hamandi B, et al. Effect of therapeutic drug monitoring and cytochrome P450 2C19 genotyping on clinical outcomes of voriconazole: a systematic review. Ann Pharmacother. 2021;55(4):509–529. doi: 10.1177/1060028020948174
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2018;24(Suppl 1):e1–e38. doi: 10.1016/j.cmi.2018.01.002
   PubMed Web of Science ®Google Scholar
• Lin X-B, Hu X-G, Tang Z-X, et al. Pharmacokinetics of voriconazole in peritoneal fluid of critically ill patients. Antimicrob Agents Chemother. 2023;67(5):e0172122. doi: 10.1128/aac.01721-22
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Abematsu K, Shigemi A, et al. Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data. J Chemother. 2016;28(3):198–202. doi: 10.1179/1973947815Y.0000000057
   PubMed Web of Science ®Google Scholar
• Kim S-H, Yim D-S, Choi S-M, et al. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2011;15(11):e753–8. doi: 10.1016/j.ijid.2011.06.004
   PubMed Web of Science ®Google Scholar
• Veringa A, Brüggemann RJ, Span LFR, et al. Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial. Int J Antimicrob Agents. 2023;61(2):106711. doi: 10.1016/j.ijantimicag.2023.106711
   PubMed Web of Science ®Google Scholar
• Gautier-Veyret E, Thiebaut-Bertrand A, Stanke-Labesque F. Comment on ‘therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial’. Int J Antimicrob Agents Netherlands. 2023;62(2):106853. doi: 10.1016/j.ijantimicag.2023.106853
   PubMed Web of Science ®Google Scholar
• Chen L, Krekels EHJ, Verweij PE, et al. Pharmacokinetics and pharmacodynamics of Posaconazole. Drugs. 2020;80(7):671–695. doi: 10.1007/s40265-020-01306-y
   PubMed Web of Science ®Google Scholar
• Maertens JA, Girmenia C, Brüggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on infections in leukaemia. J Antimicrob Chemother. 2018;73:3221–3230. doi: 10.1093/jac/dky286
   PubMed Web of Science ®Google Scholar
• Cornely OA, Alastruey-Izquierdo A, Arenz D. et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019 [cited 2022 Jun 20];19(12):e405–e421. doi: 10.1016/S1473-3099(19)30312-3
   PubMed Web of Science ®Google Scholar
• Maertens JA, Rahav G, Lee D-G, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet (London, England). 2021;397:499–509. doi: 10.1016/S0140-6736(21)00219-1
   PubMed Web of Science ®Google Scholar
• Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother. 2003;47(9):2788–2795. doi: 10.1128/AAC.47.9.2788-2795.2003
   PubMed Web of Science ®Google Scholar
• Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol. 2004;57(2):218–222. doi: 10.1046/j.1365-2125.2003.01977.x
   PubMed Web of Science ®Google Scholar
• Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother. 2007;51(3):812–818. doi: 10.1128/AAC.00454-06
   PubMed Web of Science ®Google Scholar
• Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother. 2006;50(6):1993–1999. doi: 10.1128/AAC.00157-06
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Raggam RB, Salzer HJF, et al. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents. 2012;39(6):510–513. doi: 10.1016/j.ijantimicag.2012.02.002
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Duettmann W, Raggam RB, et al. Impact of structured personal on-site patient education on low posaconazole plasma concentrations in patients with haematological malignancies. Int J Antimicrob Agents. 2014;44(2):140–144. doi: 10.1016/j.ijantimicag.2014.03.013
   PubMed Web of Science ®Google Scholar
• Vanstraelen K, Prattes J, Maertens J, et al. Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. Eur J Clin Pharmacol. 2016;72(8):953–963. doi: 10.1007/s00228-016-2057-6
   PubMed Web of Science ®Google Scholar
• Lenczuk D, Zinke-Cerwenka W, Greinix H, et al. Antifungal prophylaxis with posaconazole delayed-release tablet and oral suspension in a real-life setting: plasma levels, efficacy, and tolerability. Antimicrob Agents Chemother. 2018;62(6):62. doi: 10.1128/AAC.02655-17
   Web of Science ®Google Scholar
• Prattes J, Duettmann W, Hoenigl M. Posaconazole plasma concentrations on Days Three to Five predict steady-state levels. Antimicrob Agents Chemother. 2016;60(9):5595–5599. doi: 10.1128/AAC.00389-16
   PubMed Web of Science ®Google Scholar
• Bui J, Gellatly R, Othman J, et al. Subtherapeutic concentrations of posaconazole tablet: determining risk factors and effectiveness of a standardized dose adjustment in hematology inpatients. Leuk Lymphoma. 2022;63(14):3418–3425. doi: 10.1080/10428194.2022.2126282
   PubMed Web of Science ®Google Scholar
• Arrieta AC, Sung L, Bradley JS, et al. A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia. PLoS One. 2019;14(3):e0212837. doi: 10.1371/journal.pone.0212837
   PubMed Web of Science ®Google Scholar
• Döring M, Cabanillas Stanchi KM, Queudeville M, et al. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2017;143(7):1281–1292. doi: 10.1007/s00432-017-2369-7
   PubMed Web of Science ®Google Scholar
• Howard SJ, Lestner JM, Sharp A, et al. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J Infect Dis. 2011;203(9):1324–1332. doi: 10.1093/infdis/jir023
   PubMed Web of Science ®Google Scholar
• Lewis RE, Albert ND, Kontoyiannis DP. Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis. Antimicrob Agents Chemother. 2014;58(11):6767–6772. doi: 10.1128/AAC.03569-14
   PubMed Web of Science ®Google Scholar
• Forastiero A, Bernal-Martínez L, Mellado E, et al. In vivo efficacy of voriconazole and posaconazole therapy in a novel invertebrate model of Aspergillus fumigatus infection. Int J Antimicrob Agents. 2015;46(5):511–517. doi: 10.1016/j.ijantimicag.2015.07.007
   PubMed Web of Science ®Google Scholar
• Gastine S, Hope W, Hempel G, et al. Pharmacodynamics of Posaconazole in experimental invasive pulmonary aspergillosis: utility of serum Galactomannan as a dynamic endpoint of antifungal efficacy. Antimicrob Agents Chemother. 2021;65(2):65. doi: 10.1128/AAC.01574-20
   Web of Science ®Google Scholar
• Dolton MJ, Ray JE, Chen S-A, et al. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother. 2012;56(11):5503–5510. doi: 10.1128/AAC.00802-12
   PubMed Web of Science ®Google Scholar
• Jia M, Zhang Q, Qin Z, et al. Dose Optimisation of Posaconazole and Therapeutic Drug Monitoring in Pediatric Patients. Front Pharmacol. 2022;13:833303. doi: 10.3389/fphar.2022.833303
   PubMed Web of Science ®Google Scholar
• Jeong W, Snell GI, Levvey BJ, et al. Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations. J Antimicrob Chemother. 2018;73(3):748–756. doi: 10.1093/jac/dkx440
   PubMed Web of Science ®Google Scholar
• Kraljevic M, Khanna N, Medinger M, et al. Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients. Med Mycol. 2021;59(7):701–711. doi: 10.1093/mmy/myaa106
   PubMed Web of Science ®Google Scholar
• Tverdek FP, Heo ST, Aitken SL, et al. Real-life assessment of the safety and effectiveness of the new tablet and intravenous formulations of posaconazole in the prophylaxis of invasive fungal infections via analysis of 343 courses. Antimicrob Agents Chemother. 2017;61(8):61. doi: 10.1128/AAC.00188-17
   Web of Science ®Google Scholar
• M-RBS C, Huisman C, Kemper EM, et al. Posaconazole treatment in hematology patients: a pilot study of therapeutic drug monitoring. Ther Drug Monit. 2012;34(3):320–325. doi: 10.1097/FTD.0b013e31824d135c
   PubMed Web of Science ®Google Scholar
• Cornely OA, Ullmann AJ. Lack of evidence for exposure–response relationship in the use of Posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther United States. 2011;89(3):351–352. doi: 10.1038/clpt.2010.261
   PubMed Web of Science ®Google Scholar
• Cendejas-Bueno E, Forastiero A, Ruiz I, et al. Blood and tissue distribution of posaconazole in a rat model of invasive pulmonary aspergillosis. Diagn Microbiol Infect Dis. 2017;87(2):112–117. doi: 10.1016/j.diagmicrobio.2016.10.010
   PubMed Web of Science ®Google Scholar
• Kim HY, Märtson A-G, Dreesen E, et al. Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. Front Pharmacol. 2020;11:894. doi: 10.3389/fphar.2020.00894
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–359. doi: 10.1056/NEJMoa061094
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–347. doi: 10.1056/NEJMoa061098
   PubMed Web of Science ®Google Scholar
• Chen L, Wang Y, Zhang T, et al. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis. BMC Infect Dis. 2018;18(1):155. doi: 10.1186/s12879-018-3055-3
   PubMedGoogle Scholar
• Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis An Off Publ Infect Dis Soc Am. 2007;44(1):2–12. doi: 10.1086/508774
   PubMed Web of Science ®Google Scholar
• Dekkers BGJ, Bakker M, van der Elst KCM, et al. Therapeutic Drug Monitoring of Posaconazole: an Update. Curr Fungal Infect Rep. 2016;10(2):51–61. doi: 10.1007/s12281-016-0255-4
   PubMed Web of Science ®Google Scholar
• Kuriakose K, Nesbitt WJ, Greene M, et al. Posaconazole-Induced Pseudohyperaldosteronism. Antimicrob Agents Chemother. 2018;62(5):62. doi: 10.1128/AAC.02130-17
   Web of Science ®Google Scholar
• Davis MR, Nguyen M-V, Gintjee TJ, et al. Management of posaconazole-induced pseudohyperaldosteronism. J Antimicrob Chemother. 2020;75(12):3688–3693. doi: 10.1093/jac/dkaa366
   PubMed Web of Science ®Google Scholar
• Panos G, Velissaris D, Karamouzos V, et al. Long QT syndrome leading to multiple cardiac arrests after posaconazole administration in an immune-compromised patient with sepsis: an unusual case report. Am J Case Rep. 2016;17:295–300. doi: 10.12659/AJCR.896946
   PubMed Web of Science ®Google Scholar
• Moton A, Krishna G, Wang Z. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. J Clin Pharm Ther. 2009;34(3):301–311. doi: 10.1111/j.1365-2710.2009.01055.x
   PubMed Web of Science ®Google Scholar
• O’Flynn R, Zhou Y-P, Waskin H, et al. Hepatic safety of the antifungal triazole agent posaconazole: characterization of adverse event reports in a manufacturer’s safety database. Expert Opin Drug Saf. 2022;21(8):1113–1120. doi: 10.1080/14740338.2022.2047177
   PubMed Web of Science ®Google Scholar
• Nguyen M-V, Davis MR, Wittenberg R, et al. Posaconazole serum drug levels associated with pseudohyperaldosteronism. Clin infect dis an off publ infect dis soc Am. Clinl Infect Dis. 2020;70(12):2593–2598. doi: 10.1093/cid/ciz741
   PubMed Web of Science ®Google Scholar
• Jensen K, Saleh OA, Chesdachai S, et al. Association of adverse effects with high serum posaconazole concentrations. Med Mycol. 2023;61(8):61. doi: 10.1093/mmy/myad079
   Web of Science ®Google Scholar
• Boglione-Kerrien C, Picard S, Tron C, et al. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies. J Cancer Res Clin Oncol. 2018;144(1):127–134. doi: 10.1007/s00432-017-2523-2
   PubMed Web of Science ®Google Scholar
• Sabatino DC, Lange NW, Salerno DM, et al. Elevated posaconazole trough concentrations are not associated with increased risk for posaconazole toxicity in lung transplant recipients. Clin Transplant. 2023;37(1):e14826. doi: 10.1111/ctr.14826
   PubMed Web of Science ®Google Scholar
• Maertens JA, Rahav G, Lee D-G, et al. Pharmacokinetic and exposure response analysis of the double-blind randomized study of posaconazole and voriconazole for treatment of invasive aspergillosis. Clin Drug Investig. 2023;43(9):681–690. doi: 10.1007/s40261-023-01282-7
   PubMed Web of Science ®Google Scholar
• Pathadka S, Yan VKC, Neoh CF, et al. Global consumption trend of antifungal agents in humans from 2008 to 2018: data from 65 middle- and high-income countries. Drugs. 2022;82(11):1193–1205. doi: 10.1007/s40265-022-01751-x
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Meletiadis J, Mouton JW, et al. EUCAST technical note on isavuconazole breakpoints for aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2016;22(6):571.e1–4. doi: 10.1016/j.cmi.2016.01.017
   PubMed Web of Science ®Google Scholar
• Furfaro E, Signori A, Di Grazia C, et al. Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. J Antimicrob Chemother. 2019;74(8):2341–2346. doi: 10.1093/jac/dkz188
   PubMed Web of Science ®Google Scholar
• Gomez-Lopez A, Sanchez Galiano S, Ortega Madueño S, et al. Observed isavuconazole exposure: 5-year experience of azole TDM from a Spanish reference laboratory. Med Mycol. 2023;61:myad086. doi: 10.1093/mmy/myad086
   PubMed Web of Science ®Google Scholar
• Desai A, Kovanda L, Kowalski D, et al. Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to aspergillus and other filamentous fungi. Antimicrob Agents Chemother. 2016;60(9):5483–5491. doi: 10.1128/AAC.02819-15
   PubMed Web of Science ®Google Scholar
• Höhl R, Bertram R, Kinzig M, et al. Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis. Mycoses. 2022;65(7):747–752. doi: 10.1111/myc.13469
   PubMed Web of Science ®Google Scholar
• Zurl C, Waller M, Schwameis F, et al. Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: outcome, tolerability and clinical implications of isavuconazole plasma concentrations. J Fungi. 2020;6(2):90. (Basel, Switzerland). doi: 10.3390/jof6020090
   Web of Science ®Google Scholar
• Biagi M, Butler D, Tan X, et al. Pharmacokinetics and dialytic clearance of isavuconazole during in vitro and in vivo continuous renal replacement therapy. Antimicrob Agents Chemother. 2019;63(12):63. doi: 10.1128/AAC.01085-19
   Web of Science ®Google Scholar
• Lahmer T, Batres Baires G, Heilmaier M, et al. Influence of sustained low-efficiency dialysis treatment on isavuconazole plasma levels in critically ill patients. Antimicrob Agents Chemother. 2019;63(11):63. doi: 10.1128/AAC.01162-19
   Web of Science ®Google Scholar
• Jansen AME, Ter Heine R, Verweij PE, et al. High variability in isavuconazole unbound fraction in clinical practice: a call to reconsider Pharmacokinetic/pharmacodynamic targets and breakpoints. Clin Pharmacokinet. 2023;62(12):1695–1699. doi: 10.1007/s40262-023-01311-w
   PubMed Web of Science ®Google Scholar
• Hatzl S, Kriegl L, Posch F, et al. Early attainment of isavuconazole target concentration using an increased loading dose in critically ill patients with extracorporeal membrane oxygenation. J Antimicrob Chemother. 2023;78(12):2902–2908. doi: 10.1093/jac/dkad328
   PubMed Web of Science ®Google Scholar
• Kriegl L, Hatzl S, Zurl C, et al. Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2022;77(9):2500–2505. doi: 10.1093/jac/dkac196
   PubMed Web of Science ®Google Scholar
• Huang H, Xie H, Chaphekar N, et al. A physiologically based pharmacokinetic analysis to predict the pharmacokinetics of intravenous isavuconazole in patients with or without hepatic impairment. Antimicrob Agents Chemother. 2023;65(5):65. doi: 10.1128/AAC.02032-20
   Web of Science ®Google Scholar
• Cojutti PG, Rinaldi M, Giannella M, et al. Successful and safe real-time TDM-Guided treatment of invasive pulmonary and cerebral aspergillosis using low-dose isavuconazole in a patient with primary biliary cirrhosis: Grand Round/A Case study. Ther Drug Monit. 2023;45(2):140–142. doi: 10.1097/FTD.0000000000001064
   PubMed Web of Science ®Google Scholar
• Schwartz S, Cornely OA, Hamed K, et al. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Med Mycol. 2020;58(4):417–424. doi: 10.1093/mmy/myz103
   PubMed Web of Science ®Google Scholar
• Lamoth F, Mercier T, André P, et al. Isavuconazole brain penetration in cerebral aspergillosis. J Antimicrob Chemother England. 2019;74(6):1751–1753. doi: 10.1093/jac/dkz050
   PubMed Web of Science ®Google Scholar
• Lahmer T, Batres Baires G, Schmid RM, et al. Penetration of Isavuconazole in ascites fluid of critically Ill patients. J Fungi. 2021;7(5):376. (Basel, Switzerland). doi: 10.3390/jof7050376
   Web of Science ®Google Scholar
• Natesan SK, Chandrasekar PH. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infect Drug Resist. 2016;9:291–300. doi: 10.2147/IDR.S102207
   PubMed Web of Science ®Google Scholar
• Bury D, Wolfs TFW, Ter Heine R, et al. Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube. J Antimicrob Chemother. 2023;78(12):2886–2889. doi: 10.1093/jac/dkad324
   PubMed Web of Science ®Google Scholar
• Dieringer TD, Schaenman JM, Davis MR. Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules. J Antimicrob Chemother. 2022;77(5):1417–1423. doi: 10.1093/jac/dkac035
   PubMed Web of Science ®Google Scholar
• Cojutti PG, Carnelutti A, Lazzarotto D, et al. Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against aspergillus fumigatus and aspergillus flavus in adult patients with invasive fungal diseases: should therapeutic drug monitoring for isavuconazole Be considered as mandatory as for the other Mold-Active Azoles? Pharmaceutics. 2021;13(12). doi: 10.3390/pharmaceutics13122099
   PubMed Web of Science ®Google Scholar
• Risum M, Vestergaard M-B, Weinreich UM, et al. Therapeutic drug monitoring of Isavuconazole: serum concentration variability and success rates for reaching target in comparison with Voriconazole. Antibiot. 2021;10(5):487. (Basel, Switzerland). doi: 10.3390/antibiotics10050487
   Google Scholar
• Chen Y-C, Chang T-Y, Liu J-W, et al. Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study. BMC Infect Dis. 2015;15(1):277. doi: 10.1186/s12879-015-1023-8
   PubMedGoogle Scholar
• Pfaller MA, Diekema DJ, Turnidge JD, et al. Twenty years of the SENTRY antifungal surveillance program: results for candida species from 1997–2016. Open Forum Infect Dis. 2019;6:S79–S94. doi: 10.1093/ofid/ofy358
   PubMed Web of Science ®Google Scholar
• Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet. 1993;24(1):10–27. doi: 10.2165/00003088-199324010-00002
   PubMed Web of Science ®Google Scholar
• Debruyne D, Ryckelynck JP, Moulin M, et al. Pharmacokinetics of fluconazole in patients undergoing continuous ambulatory peritoneal dialysis. Clin Pharmacokinet. 1990;18(6):491–498. doi: 10.2165/00003088-199018060-00006
   PubMed Web of Science ®Google Scholar
• Toon S, Ross CE, Gokal R, et al. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol. 1990;29(2):221–226. doi: 10.1111/j.1365-2125.1990.tb03623.x
   PubMed Web of Science ®Google Scholar
• Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985;28(5):648–653. doi: 10.1128/AAC.28.5.648
   PubMed Web of Science ®Google Scholar
• Buijk SL, Gyssens IC, Mouton JW, et al. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive care Med. 2001;27(1):115–121. doi: 10.1007/s001340000771
   PubMed Web of Science ®Google Scholar
• Muilwijk EW, de Lange DW, Schouten JA, et al. Suboptimal dosing of fluconazole in critically ill patients: time to rethink dosing. Antimicrob Agents Chemother. 2020;64(10):64. doi: 10.1128/AAC.00984-20
   Web of Science ®Google Scholar
• Bienvenu AL, Pradat P, Matusik E, et al. Suboptimal exposure to fluconazole in critically ill patients: pharmacokinetic analysis and determinants. Infect Dis Now. 2023;53(2):104630. doi: 10.1016/j.idnow.2022.10.002
   PubMedGoogle Scholar
• Van Daele R, Wauters J, Lagrou K, et al. Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients. Microorganisms. 2021;9(10):2068. doi: 10.3390/microorganisms9102068
   PubMed Web of Science ®Google Scholar
• Chen L, van Rhee KP, Wasmann RE, et al. Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults. J Antimicrob Chemother. 2022;77(8):2217–2226. doi: 10.1093/jac/dkac160
   PubMed Web of Science ®Google Scholar
• Pea F, Righi E, Cojutti P, et al. Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis. J Antimicrob Chemother England. 2014;69(9):2585–2586. doi: 10.1093/jac/dku169
   PubMed Web of Science ®Google Scholar
• Louie A, Drusano GL, Banerjee P, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother. 1998;42(5):1105–1109. doi: 10.1128/AAC.42.5.1105
   PubMed Web of Science ®Google Scholar
• Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother. 1999;43(9):2116–2120. doi: 10.1128/AAC.43.9.2116
   PubMed Web of Science ®Google Scholar
• Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007;51(1):35–39. doi: 10.1128/AAC.00474-06
   PubMed Web of Science ®Google Scholar
• Boonstra JM, Märtson AG, Sandaradura I, et al. Optimization of fluconazole dosing for the prevention and treatment of invasive candidiasis based on the Pharmacokinetics of fluconazole in critically ill patients. Antimicrob Agents Chemother. 2021;65(3):65. doi: 10.1128/AAC.01554-20
   Web of Science ®Google Scholar
• EUCAST. European Committee on Antimicrobial Susceptibility Testing. Fluconazole: Rationale for the clinical breakpoints, version 3.0. 2020. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Fluconazole_RD_v3.0_final_18_02.pdf
   Google Scholar
• Righi E, Carnelutti A, Baccarani U, et al. Treatment of Candida infections with fluconazole in adult liver transplant recipients: is TDM-guided dosing adaptation helpful? Transpl Infect Dis An Off J Transplant Soc. 2019;21(4):e13113. doi: 10.1111/tid.13113
   PubMed Web of Science ®Google Scholar
• Di Leo E, Nettis E, Priore MG, et al. Maculopapular rash due to fluconazole. Clin Exp Dermatol England. 2009;34(3):404. doi: 10.1111/j.1365-2230.2008.02895.x
   PubMed Web of Science ®Google Scholar
• Kyriakidis I, Tragiannidis A, Munchen S, et al. Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf. 2017;16(2):149–165. doi: 10.1080/14740338.2017.1270264
   PubMed Web of Science ®Google Scholar
• Yüksekgönül A Ü, İ E, Karagöz T. Fluconazole-associated QT interval prolongation and Torsades de Pointes in a paediatric patient. Cardiol Young. 2021;31(12):2035–2037. doi: 10.1017/S1047951121001992
   PubMed Web of Science ®Google Scholar